Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00457002 · ClinicalTrials.gov registry record · Phase 3
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,758
- Enrollment target
NCT00457002 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 6,758 participants.
The verdict
NCT00457002, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,758 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein thrombosis \[DVT\]) and lung (pulmonary embolism \[PE\]) that sometimes occur within patients hospitalized for acute medical illness, and to learn how apixaban compares to enoxaparin (Lovenox®) for preventing these clots. The safety of apixaban will also be studied.
Interventions
- DRUG Apixaban
- DRUG Enoxaparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,758 participants |
| Start Date | 2007-06 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00457002
The ClinicalTrials.gov registry entry for NCT00457002 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 6,758 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT00457002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00457002 about?
NCT00457002 is a clinical study titled "Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness". The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein thrombosis \[DVT\]) and lung (pulmonary embolism \[PE\]) that sometimes occur within patients hospitalized for acute medical illness, and to learn how apixaban compares to enoxaparin (Lovenox®) for preven...
What is the current status of trial NCT00457002?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,758 participants. The study started on 2007-06. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00457002?
The interventions under investigation include: Apixaban (DRUG), Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT00457002?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.